Robert A.  Cascella net worth and biography

Robert Cascella Biography and Net Worth

Director of Neuronetics
Robert A. Cascella is an American businessperson who has been at the head of 7 different companies and occupies the position of Chairman of Neuronetics, Inc., Chief Executive Officer at Philips Medical Systems MR, Inc. and President & Chief Executive Officer at Invivo Corp. Mr. Cascella is also on the board of Celestica, Inc., Metabolon, Inc. and Mirion Technologies, Inc.

Robert A. Cascella previously occupied the position of Chairman at DySIS Medical Ltd., Chairman for Miranda Medical Centre, President, Chief Executive Officer & Director at Hologic, Inc., President, Chief Operating & Financial Officer at Fischer Imaging Corp., Chief Business Leader-Diagnosis & Treatment, EVP at Koninklijke Philips NV, Managing Partner at CFG Capital LLC, Director-Accounting & Financial Planning at PerkinElmer, Inc. (United States), Chief Operating Officer & VP-Finance at NeoVision Corp. and Principal at American Cancer Society, Inc.

He received an undergraduate degree from Fairfield University.

What is Robert A. Cascella's net worth?

The estimated net worth of Robert A. Cascella is at least $267,373.13 as of September 12th, 2024. Mr. Cascella owns 453,098 shares of Neuronetics stock worth more than $267,373 as of November 12th. This net worth estimate does not reflect any other investments that Mr. Cascella may own. Learn More about Robert A. Cascella's net worth.

How do I contact Robert A. Cascella?

The corporate mailing address for Mr. Cascella and other Neuronetics executives is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. Neuronetics can also be reached via phone at (610) 640-4202 and via email at [email protected]. Learn More on Robert A. Cascella's contact information.

Has Robert A. Cascella been buying or selling shares of Neuronetics?

Robert A. Cascella has not been actively trading shares of Neuronetics over the course of the past ninety days. Most recently, on Thursday, September 12th, Robert Cascella bought 100,000 shares of Neuronetics stock. The stock was acquired at an average cost of $0.75 per share, with a total value of $75,000.00. Following the completion of the transaction, the director now directly owns 453,098 shares of the company's stock, valued at $339,823.50. Learn More on Robert A. Cascella's trading history.

Who are Neuronetics' active insiders?

Neuronetics' insider roster includes Robert Cascella (Director), Sheryl Conley (Director), Stephen Furlong (CFO), Gregory Harper (VP), William Macan (VP), Bruce Shook (Director), and Keith Sullivan (CEO). Learn More on Neuronetics' active insiders.

Are insiders buying or selling shares of Neuronetics?

In the last twelve months, Neuronetics insiders bought shares 7 times. They purchased a total of 261,776 shares worth more than $277,669.60. In the last twelve months, insiders at the sold shares 16 times. They sold a total of 222,765 shares worth more than $646,181.07. The most recent insider tranaction occured on October, 8th when CFO Stephen Furlong sold 1,368 shares worth more than $1,121.76. Insiders at Neuronetics own 9.8% of the company. Learn More about insider trades at Neuronetics.

Information on this page was last updated on 10/8/2024.

Robert A. Cascella Insider Trading History at Neuronetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/12/2024Buy100,000$0.75$75,000.00453,098View SEC Filing Icon  
8/19/2024Buy4,000$1.14$4,560.00353,098View SEC Filing Icon  
8/16/2024Buy35,000$1.06$37,100.00349,098View SEC Filing Icon  
8/14/2024Buy35,000$0.79$27,650.00279,098View SEC Filing Icon  
6/6/2024Buy50,000$2.05$102,500.00244,098View SEC Filing Icon  
11/22/2021Buy15,000$4.10$61,500.00View SEC Filing Icon  
8/30/2021Buy15,000$6.72$100,800.00View SEC Filing Icon  
See Full Table

Robert A. Cascella Buying and Selling Activity at Neuronetics

This chart shows Robert Cascella's buying and selling at Neuronetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neuronetics Company Overview

Neuronetics logo
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.68
Low: $0.52
High: $0.80

50 Day Range

MA: $0.91
Low: $0.73
High: $1.19

2 Week Range

Now: $0.68
Low: $0.52
High: $5.07

Volume

6,274,284 shs

Average Volume

274,210 shs

Market Capitalization

$20.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21